Published in Clin Cosmet Investig Dermatol on January 27, 2009
FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) (1987) 7.07
The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol (1989) 4.30
Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry (1992) 3.05
Systematic review of treatments for atopic eczema. Health Technol Assess (2000) 2.65
Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol (2000) 2.46
The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol (2000) 2.26
New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol (2006) 2.06
Genetic risk for asthma, allergic rhinitis, and atopic dermatitis. Arch Dis Child (1992) 1.96
Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol (2002) 1.71
Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol (2002) 1.56
0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol (2004) 1.53
Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol (2001) 1.45
The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol (1994) 1.42
Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study. Pediatrics (2005) 1.39
Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol (2006) 1.33
Immune dysregulation in atopic dermatitis. Curr Allergy Asthma Rep (2006) 1.29
Itch and atopic dermatitis: an overview. J Dermatol (1999) 1.27
The occurrence of atopic dermatitis in north Europe: an international questionnaire study. J Am Acad Dermatol (1996) 1.27
Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol (2002) 1.23
Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol (2002) 1.18
Effects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12. Proc Natl Acad Sci U S A (1992) 1.11
Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol (2001) 1.09
Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol (2001) 1.07
A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol (2001) 0.95
The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. Br J Dermatol (2007) 0.95
Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol (2005) 0.94
Skin barrier function in atopic dermatitis. Curr Opin Pediatr (2007) 0.94
Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol (2000) 0.94
A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol (2007) 0.93
Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol (2001) 0.92
Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol (2005) 0.89
Clinical features of atopic dermatitis at two years of age: a prospective, population-based case-control study. Acta Derm Venereol (2001) 0.88
Systemic treatment of severe atopic eczema: a systematic review. Acta Derm Venereol (2007) 0.88
The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. Mol Cell Biol (1991) 0.88
Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol (1998) 0.86
Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clin Exp Allergy (2004) 0.86
Corticosteroid-induced cutaneous atrophy and telangiectasia. Experimental production associated with weight loss in rats. Arch Dermatol (1976) 0.85
The treatment of atopic dermatitis with topical immunomodulators. Clin Dermatol (2003) 0.84
A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol (2005) 0.84
Treatment of atopic dermatitis: role of tacrolimus ointment as a topical noncorticosteroidal therapy. J Allergy Clin Immunol (1999) 0.84
Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Derm Venereol (2007) 0.82
Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol (2002) 0.81
A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol (2005) 0.81
Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol (1998) 0.81
Effects of oral administration of ciclosporin A on skin carcinogenesis: a study using the two-stage carcinogenesis protocol in mice. Clin Exp Dermatol (2008) 0.78
Atopic dermatitis management with tacrolimus ointment (Protopic). J Dermatolog Treat (2003) 0.78
Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol (2001) 0.78
Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Br J Dermatol (2000) 0.77
Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (Fk506). J Invest Dermatol (2001) 0.77
A case of chronic actinic dermatitis treated with topical tacrolimus. J Dermatolog Treat (2005) 0.76
Topical immunomodulators for atopic dermatitis. Curr Opin Pediatr (2002) 0.76
[Epidemiology and pathophysiology of eczemas]. Rev Prat (2006) 0.76
Possible inhibitory mechanism of FK506 (tacrolimus hydrate) ointment for atopic dermatitis based on animal models. Eur J Pharmacol (1999) 0.75
Zoon's Balanitis: Benign or Premalignant Lesion? Case Rep Dermatol (2009) 0.83
Psoriatic disease and tuberculosis nowadays. Clin Dev Immunol (2012) 0.81
Effect of weather and environmental factors on the clinical course of psoriasis. Occup Environ Med (2013) 0.79
Differential diagnosis of psoriasis. J Rheumatol Suppl (2009) 0.79
Anti-Tumor Necrosis Factor-α Therapy in the Management of Psoriasis and B-Chronic Lymphocytic Leukemia. Case Rep Dermatol (2011) 0.78
Contact sensitization of older patients in an academic department in Naples, Italy. Dermatitis (2008) 0.77
Contact sensitization in the elderly. Clin Dermatol (2010) 0.77
Skin needling in the treatment of the aging neck. Skinmed (2012) 0.76
Contact allergy to p-tert-butylphenol formaldehyde resin and zinc diethyldithiocarbamate in a wet suit. Dermatitis (2008) 0.76
Scratch-patch test for the diagnosis of allergic contact dermatitis to aciclovir. Contact Dermatitis (2009) 0.75
Polymorphous light eruption and benign summer light eruption in Italy. Photodermatol Photoimmunol Photomed (2011) 0.75
In vitro ultraviolet A irradiation decreases both release ability and gene-expression of vascular endothelial growth factor-A from mast cells. Photodermatol Photoimmunol Photomed (2012) 0.75